Caption Management’s Cellebrite CLBT Stock Holding History

Caption Management’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-150,000	Closed	-$2.7M	–	1622
2025 Q4	$2.7M	Buy	+150,000	New	+$2.69M	0.02%	727

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Caption Management's CLBT Position: Q1 2026 in Review

Caption Management sold out of Cellebrite (CLBT) in Q1 2026, closing a stake of 48,000 shares — an estimated $723K sold.

Caption Management first reported a position in CLBT in Q3 2021 and held it in 4 quarters. The position peaked at $898K in Q3 2024. 220 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

Caption Management reported no remaining Cellebrite position as of Q1 2026 after selling out during the quarter.
Caption Management sold 48,000 Cellebrite shares in Q1 2026, an estimated $723K.
Caption Management first reported a position in Cellebrite in Q3 2021 and held it in 4 quarters.
Caption Management's Cellebrite position peaked at $898K in Q3 2024.
220 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.